SCHEMBL2745828

SCHEMBL2745828

CC(=O)N(C(C)=O)c1nc(O)c2ncc(C(O)C(C)O)nc2n1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.33
APLNR P35414 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2746213 0.77 KDM4E (0.34) HSD17B10
Hydrochloric Acid SCHEMBL8575908 0.74 HSD17B10 (0.39) HSD17B10APLNR
SCHEMBL30515237 0.64 HSD17B10 (0.68) HSD17B10
SCHEMBL4365313 0.60 KMT2A (0.41) HSD17B10
SCHEMBL15952738 0.58 KDM4E (0.38) HSD17B10
SCHEMBL23028961 0.57 HSD17B10 (0.49) HSD17B10
SCHEMBL13947293 0.56 HSD17B10 (0.85) HSD17B10
SCHEMBL258468 0.56 HSD17B10 (0.85) HSD17B10
SCHEMBL29776986 0.56 HSD17B10 (0.85) HSD17B10
SCHEMBL29400382 0.56 HSD17B10 (0.85) HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110872293-A Chemical synthesis and purification method of biopterin 北京启慧生物医药有限公司 2020-03-10 CN claimed
WO-2016189542-A1 NOVEL PROCESS FOR THE PREPARATION OF SAPROPTERIN DIHYDROCHLORIDE AND ITS KEY INTERMEDIATE, L-BIOPTERIN NATCO PHARMA LTD (IN) 2016-12-01 WO claimed
US-8178670-B2 Method of synthesizing tetrahydrobiopterin BIOMARIN PHARMACEUTICAL INC. (US) 2012-05-15 US claimed
EP-2240484-A1 METHOD OF SYNTHESIZING TETRAHYDROBIOPTERIN BioMarin Pharmaceutical Inc. (US) 2010-10-20 EP claimed
US-20090198055-A1 METHOD OF SYNTHESIZING TETRAHYDROBIOPTERIN BIOMARIN PHARMACEUTICAL INC. (US) 2009-08-06 US claimed
WO-2009088979-A1 METHOD OF SYNTHESIZING TETRAHYDROBIOPTERIN BIOMARIN PHARMACEUTICAL INC. (US) 2009-07-16 WO claimed
US-5043446-A Subjecting ribose to acetalization, Grignard, oxidative cleavage, hydrazoning, condensing with pyridine to 1-biopterin NISSHIN FLOUR MILLING CO., LTD. (JP) 1991-08-27 US claimed
US-12605386-B2 Sapropterin formulation APR APPLIED PHARMA RESEARCH SA (CH) 2026-04-21 US disclosed
US-20250339439-A1 Sapropterin Formulation APR APPLIED PHARMA RESEARCH SA (CH) 2025-11-06 US disclosed
CN-118984698-A Sapropterin formulations APR应用制药研究股份有限公司 2024-11-19 CN disclosed
WO-2023148662-A1 SAPROPTERIN FORMULATION APR APPLIED PHARMA RESEARCH S.A. (CH) 2023-08-10 WO disclosed
US-20230241069-A1 Sapropterin Formulation APR APPLIED PHARMA RESEARCH SA (CH) 2023-08-03 US disclosed
CN-110872293-A Chemical synthesis and purification method of biopterin 北京启慧生物医药有限公司 2020-03-10 CN disclosed
US-5043446-A Subjecting ribose to acetalization, Grignard, oxidative cleavage, hydrazoning, condensing with pyridine to 1-biopterin NISSHIN FLOUR MILLING CO., LTD. (JP) 1991-08-27 US disclosed
EP-0385336-A2 Processes for the preparation of pterin derivatives NISSHIN FLOUR MILLING CO., LTD. (JP) 1990-09-05 EP disclosed
EP-0079574-B1 PROCESS FOR PREPARING BIOPTERIN AND ITS DERIVATIVES KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-03-04 EP disclosed
EP-0164964-A1 Lipoidal biopterin compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1985-12-18 EP disclosed
US-4550109-A PHENYLKETONURIA, PARKINSON'S DISEASE, DEPRESSION, SENILE DEMENTIA,ALZHEIMER'S DISEASE THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1985-10-29 US disclosed
US-4540783-A 1',2'-Diacyl-(6R,S)-5,6,7,8-tetrahydro-L-biopterin and process for preparing the same KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1985-09-10 US disclosed
EP-0079574-A1 Process for preparing biopterin and its derivatives KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1983-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250339439-A1 Sapropterin Formulation PSAP, CYP46A1, HSD11B2 HSD17B10 154/4885APLNR 651/4885
US-20090198055-A1 METHOD OF SYNTHESIZING TETRAHYDROBIOPTERIN SPR, THOP1, PTMA HSD17B10 854/4885APLNR 199/4885
US-20230241069-A1 Sapropterin Formulation PSAP, CYP46A1, HSD11B2 HSD17B10 154/4885APLNR 651/4885
US-12605386-B2 Sapropterin formulation PAH, CYP46A1, CYP21A2 HSD17B10 11/4885APLNR 2145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.